| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Erteberel (also known as LY500307) is a novel, potent and selective estrogen receptor beta (ERβ) inhibitor with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. It has anti-tumor activities and was developed for the treatment of benign prostatic hyperplasia. LY500307 was well tolerated in BPH patients with LUTS at doses up to 25 mg once daily for 24 weeks. The study was terminated early because of inadequate efficacy.
| ln Vitro |
In vitro, Erteberel treatment (0.25-10 μM, 72 hours) significantly inhibited GBM cell proliferation but had no effect on normal astrocytes [2]. Erteberel induces apoptosis in GBM cells. Erteberel affects several processes linked to the cell cycle, DNA damage response, and apoptosis [2]. Erteberel (0-1000 μM) sensitizes GBM cells to a number of chemotherapeutic medications that are licensed by the FDA, such as temozolomide, lomustine, and cisplatin [2].
|
|---|---|
| ln Vivo |
Erteberel treatment (5 mg/Kg body weight/day, oral, for 28 days) significantly slowed tumor growth and increased GBM tumor cell apoptosis in an orthotopic model [2]. In the GL26 syngeneic glioma model, ERTEBEL (5 mg/Kg body weight/day, oral, 40–50 days) treatment increases the overall survival of tumor-bearing mice [2].
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: U87, U251, T98G and normal astrocytes Tested Concentrations: 0.25, 0.5, 1, 2, 4, 6, 8 and 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Erteberel treatment Dramatically diminished viability was studied in various GBM cell lines in a dose-dependent manner. In contrast, the viability of normal astrocytes was not affected at the tested doses, indicating that Erteberel has tumor cell-specific activity [2]. |
| Animal Protocol |
Animal/Disease Models: Athymic mice (5-7 weeks) vaccinated with OVCAR-3 cells [2]
Doses: 5 mg/kg body weight Route of Administration: Orally, one time/day for 28 days Experimental Results: Immunohistochemical analysis demonstrated that Erteberel Treatment Dramatically diminished the number of proliferation marker Ki-67-positive cells and increased the number of TUNEL-positive apoptotic cells [2]. |
| References |
|
| Additional Infomation |
Erteberel is an estrogen receptor beta agonist that has been used in trials studying the treatment of Benign Prostatic Hyperplasia.
|
| Molecular Formula |
C18H18O3
|
|---|---|
| Molecular Weight |
282.333725452423
|
| Exact Mass |
282.125
|
| CAS # |
533884-09-2
|
| PubChem CID |
10286159
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.268
|
| Boiling Point |
485.2±45.0 °C at 760 mmHg
|
| Flash Point |
247.3±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
3.84
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
21
|
| Complexity |
364
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1C[C@H]2[C@@H](C1)C3=C(C=CC(=C3)O)O[C@H]2C4=CC=C(C=C4)O
|
| InChi Key |
XIESSJVMWNJCGZ-VKJFTORMSA-N
|
| InChi Code |
InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1
|
| Chemical Name |
(3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
|
| Synonyms |
LY500307; LY-500307; LY 500307
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 30 mg/mL (~106.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5420 mL | 17.7098 mL | 35.4195 mL | |
| 5 mM | 0.7084 mL | 3.5420 mL | 7.0839 mL | |
| 10 mM | 0.3542 mL | 1.7710 mL | 3.5420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA